Spyre Therapeutics (SYRE) Other Gross PP&E Adjustments (2016 - 2025)
Spyre Therapeutics (SYRE) has disclosed Other Gross PP&E Adjustments for 11 consecutive years, with -$12.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments fell 81.94% year-over-year to -$12.9 million, compared with a TTM value of -$12.9 million through Dec 2025, down 81.94%, and an annual FY2025 reading of -$12.9 million, down 81.94% over the prior year.
- Other Gross PP&E Adjustments was -$12.9 million for Q4 2025 at Spyre Therapeutics, down from -$7.1 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $3.8 million in Q4 2021 and bottomed at -$12.9 million in Q4 2025.
- Average Other Gross PP&E Adjustments over 5 years is -$4.8 million, with a median of -$5.3 million recorded in 2021.
- Peak annual rise in Other Gross PP&E Adjustments hit 34.28% in 2023, while the deepest fall reached 762.4% in 2023.
- Year by year, Other Gross PP&E Adjustments stood at $3.8 million in 2021, then plummeted by 83.07% to $641000.0 in 2022, then tumbled by 762.4% to -$4.2 million in 2023, then plummeted by 67.55% to -$7.1 million in 2024, then tumbled by 81.94% to -$12.9 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for SYRE at -$12.9 million in Q4 2025, -$7.1 million in Q4 2024, and -$4.2 million in Q4 2023.